Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06642545 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 17, 2025 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date changed from estimate of Feb 17, 2025 to Feb 10, 2025v4
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Nov 1, 2024 to Feb 17, 2025 · Site details revisedv3 Show 2 more changesShow less
    • Start date: Nov 1, 2024 to Feb 17, 2025
    • Site details revised
  3. Interventions: Disitamab Vedotin (Drug), RC148 (Drug) to Albumin-bound Paclitaxone (Drug), Disitamab Vedotin (Drug), RC148 (Drug), Toripalimab (Drug) Eligibility criteria shortened, about 25 wordsv2 Show 1 more changeShow less
    • Eligibility criteria shortened, about 25 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer
Trial Details
NCT Number NCT06642545
Lead Sponsor RemeGen Co., Ltd.
Conditions Breast Cancer
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov